EarningsQ4 2024 Earnings Report
MX:4503N Q4 2024 EPS Results
Actual EPS$4.85
Consensus EPS$2.47
Beat/MissBeat by +$2.38
One Year Ago EPS-$2.15
MX:4503N Q4 2024 Revenue Results
Actual Revenue$53.28B
Expected Revenue$51.33B
Beat/MissBeat by +$1.95B
YoY Revenue Growth+10.78%
Earnings Announcement Details
QuarterQ4 2024
Date04/25/2025
TimeBefore Open
Conference CallFriday, April 25, 2025
MX:4503N Upcoming Earnings
Astellas Pharma's next earnings date is estimated for November 4, 2026, based on past reporting schedules.
Q4 2024 Earnings Call Audio
MX:4503N Q4 2024 Earnings Call
0:00 / 0:00
Q4 2024 Earnings Slide Deck
Q4 2024 Earnings Call Summary
Earnings Call Sentiment|Positive
Astellas Pharma demonstrated strong financial performance with record-breaking revenue and significant growth in Strategic Brands. Successful cost optimization and a positive outlook for FY 2025, including increased dividends and progress in primary focus programs, highlight a positive trajectory. Despite challenges such as the impact of U.S. Medicare Part D redesign and temporary demand issues with IZERVAY, the overall sentiment remains optimistic.Company Guidance
Record-Breaking Revenue and Growth
In FY 2024, Astellas Pharma reported record high revenue of ¥1.912 trillion, a 19.2% increase year-on-year, and core operating profit of ¥392.4 billion, up by 41.7% year-on-year.
Strategic Brands Driving Growth
Sales of Strategic Brands, including PADCEV, IZERVAY, VEOZAH, VYLOY, and XOSPATA, exceeded ¥340 billion, more than doubling with a growth of ¥180 billion or 110% year-on-year.
Cost Optimization Success
Astellas Pharma achieved its cost optimization target of ¥40 billion in FY 2024, improving the SG&A ratio by 3.1 percentage points year-on-year.
Strong Outlook for FY 2025
Astellas expects continued strong momentum in Strategic Brands with projected revenue of ¥1.930 trillion and underlying growth excluding Forex impact expected to be 7%.
Dividend Increase
Astellas increased its dividend per share to ¥78, an increase of ¥4, in anticipation of future profit growth.
Primary Focus Program Progress
ASB-3082 achieved proof of concept (PoC) in pancreatic ductal adenocarcinoma, marking a significant milestone in targeted protein degradation.
MX:4503N Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed